XILIO THERAPEUTICS INC (XLO)
US98422T1007 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to XLO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.59. This target is 414.57% above the current price.
XLO was analyzed by 7 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about XLO.
In the previous month the buy percentage consensus was at a similar level.
XLO was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-05-30 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Overweight |
| 2022-12-21 | Chardan Capital | Initiate | Buy |
| 2022-11-10 | Raymond James | Maintains | Outperform |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-01-10 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-16 | Cowen & Co. | Initiate | Outperform |
| 2021-11-16 | Raymond James | Initiate | Outperform |
| 2021-11-16 | Morgan Stanley | Initiate | Overweight |